Drug Profile
Research programme: urological and metabolic disorders therapeutics - 4SC/Schwarz Pharma
Alternative Names: SC-76803Latest Information Update: 16 Jan 2008
Price :
$50
*
At a glance
- Originator 4SC; Schwarz Pharma
- Developer 4SC
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Erectile dysfunction; Genitourinary disorders
Most Recent Events
- 16 Jan 2008 Discontinued - Preclinical for Asthma in Germany (unspecified route)
- 16 Jan 2008 Discontinued - Preclinical for Erectile dysfunction in Germany (unspecified route)
- 16 Jan 2008 Discontinued - Preclinical for Genitourinary disorders in Germany (unspecified route)